We are live on ! Find out more
PLRZ icon

Polyrizon

9.31 USD
-0.86
8.46%
At close Updated Nov 20, 4:00 PM EST
1 day
-8.46%
5 days
-11.33%
1 month
1.75%
3 months
-11.25%
6 months
-31.29%
Year to date
-26.98%
1 year
165.24%
5 years
-99.6%
10 years
-99.6%
 

About: Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. The company's technology platforms are Capture & Contain and Trap & Target.

Employees: 1

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
GlobeNewsWire
11 days ago
POLYRIZON ADOPTS LIMITED DURATION SHAREHOLDER RIGHTS PLAN
TEL AVIV, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that its Board of Directors (the “Board”) has unanimously adopted a limited duration shareholder rights plan (the "Rights Plan"), effective immediately.
POLYRIZON ADOPTS LIMITED DURATION SHAREHOLDER RIGHTS PLAN
Neutral
GlobeNewsWire
25 days ago
Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker
All 120 planned participants randomized across five clinical sites in the United States Raanana, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a clinical-stage biotechnology company specializing in the development of innovative intranasal hydrogels, today announced the successful completion of patient enrollment and randomization in its U.S. multicenter clinical study evaluating NASARIX, the Company's proprietary investigational nasal hydrogel product candidate designed to provide protection against airborne allergens.
Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker
Neutral
GlobeNewsWire
1 month ago
Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform
A new patent application covers Polyrizon's proprietary mucoadhesive platform and its potential applications in nasal drug delivery.
Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform
Neutral
GlobeNewsWire
2 months ago
Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker
First patient marks Polyrizon's transition into a clinical-stage company. The U.S clinical study is designed to evaluate the efficacy, safety and tolerability of the NASARIX (PL-14) Allergy Blocker in patients with seasonal allergic rhinitis Raanana, Israel, Sept.
Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker
Neutral
GlobeNewsWire
2 months ago
Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement
RAANANA, ISRAEL, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd.
Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement
Neutral
GlobeNewsWire
2 months ago
Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement
RAANANA, ISRAEL, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that it has entered into definitive agreements with a single institutional investor for the purchase and sale of its Ordinary Shares and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also agreed to sell to the same investor pre-funded and investor warrants. Aggregate gross proceeds to the Company from both transactions are expected to be approximately $4.0 million.
Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement
Neutral
GlobeNewsWire
2 months ago
Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study
Raanana, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, recently announced that it has completed contracting with the fourth and fifth clinical sites participating in its clinical study of NASARIX™ Allergy Blocker (PL-14).
Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study
Neutral
GlobeNewsWire
3 months ago
Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment
Polyrizon completes contracting with all five U.S. clinical sites and advances its NASARIX™ study toward enrollment of 120 patients Raanana, Israel, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that it has completed contracting with the fourth and fifth clinical sites participating in its clinical study of NASARIX™ Allergy Blocker (PL-14).
Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment
Neutral
GlobeNewsWire
4 months ago
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
Raanana, Israel, July 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced successful results from its biocompatibility evaluation program for its proprietary NASARIXTM Allergy Blocker nasal spray, with all required biological safety tests meeting their predetermined acceptance criteria.
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
Neutral
GlobeNewsWire
4 months ago
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
Raanana, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, announced it has received central IRB approval to begin its first human clinical trial for NASARIX™, the Company's innovative nasal spray designed to block airborne allergens.
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
Price charts implemented using Lightweight Charts™